

**DESCRIPTION**

<b>Source</b>	Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein Val16-Lys1211(Gly142Asp, Glu154Lys, Leu452Arg, Glu484Gln, Asp614Gly, Pro681Arg, Gln1071His) (Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro), with a C-terminal 6-His tag Accession # YP_009724390.1
<b>N-terminal Sequence Analysis</b>	Val16
<b>Predicted Molecular Mass</b>	134 kDa

**SPECIFICATIONS**


<b>SDS-PAGE</b>	153-170 kDa, under reducing conditions.
<b>Activity</b>	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 500 µg/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>


**DATA**

**Binding Activity**



**Recombinant SARS-CoV-2 B.1.617.1 Spike His-tag Protein Binding Activity.** Recombinant SARS-CoV-2 B.1.617.1 Spike His-tag (Catalog # 10978-CV) binds Recombinant Human ACE-2 His-tag (Catalog # 933-ZN) in a functional ELISA.

**SDS-PAGE**



**Recombinant SARS-CoV-2 B.1.617.1 Spike His-tag Protein SDS-PAGE.** 2 µg/lane of Recombinant SARS-CoV-2 B.1.617.1 Spike His-tag Protein (Catalog # 10978-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 150-170 kDa.

## BACKGROUND

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). A metalloproteinase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV-2 through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (6, 7). The S protein of SARS-CoV-2 shares 75% and 29% amino acid (aa) sequence identity with the S protein of SARS-CoV-1 and MERS, respectively. A SARS-CoV-2 variant (B.1.617.1) carrying the aa substitution Gly142Asp, Glu154Lys, Leu452Arg, Glu484Gln, Asp614Gly, Pro681Arg, and Gln1071His in the S protein was identified as a prevalent strain in India (8, 9). Whether these mutations would cause more severe symptom or decrease the efficacy of vaccine-induced immunity is still under investigation.

## References:

1. Wu, F. *et al.* (2020) *Nature* **579**:265.
2. Tortorici, M.A. and D. Veesele (2019) *Adv. Virus Res.* **105**:93.
3. Bosch, B.J. *et al.* (2003). *J. Virol.* **77**:8801.
4. Belouzard, S. *et al.* (2009) *Proc. Natl. Acad. Sci.* **106**:5871.
5. Millet, J.K. and G.R. Whittaker (2015) *Virus Res.* **202**:120.
6. Li, W. *et al.* (2003) *Nature* **426**:450.
7. Wong, S.K. *et al.* (2004) *J. Biol. Chem.* **279**:3197.
8. Yadav, P.D. *et al.* (2021) bioRxiv <https://doi.org/10.1101/2021.04.23.441101>.
9. Cherian, S. *et al.* (2021) bioRxiv <https://doi.org/10.1101/2021.04.22.440932>.